Section Edited by Howard L. Kaufman, MD, FACS
This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.
Intratumoral administration of the immunologic adjuvant AS01 in combination with autologous CD1c (BDCA-1)/CD141 (BDCA-3) myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanomaJens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns
11 January 2024
RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironmentYuan Meng, Haotian Liu, Haoran Zhu, Wanrong Zhang, Dong Sun, Xuefei Han, Ying Liu, Guangzuo Luo
11 January 2024
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trialKelley Coffman-D'Annibale, Yuta Myojin, Cecilia Monge, Changqing Xie, Donna Mabry Hrones, Bradford J Wood, Elliot B Levy, David Kleiner, William Douglas Figg, Seth M Steinberg, Bernadette Redd, Tim F Greten
6 January 2024
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancerKurt A Jenkins, Miso Park, Magali Pederzoli-Ribeil, Ugur Eskiocak, Parker Johnson, Wilson Guzman, Megan McLaughlin, Deborah Moore-Lai, Caitlin O’Toole, Zhen Liu, Benjamin Nicholson, Veronica Flesch, Huawei Qiu, Tim Clackson, Ronan C O’HaganSee the full list of authors
12 December 2023
Local and distant response to intratumoral immunotherapy assessed by immunoPET in miceLouis Meyblum, Céline Chevaleyre, Sandrine Susini, Benoit Jego, Frederic Deschamps, Dimitri Kereselidze, Baptiste Bonnet, Aurelien Marabelle, Thierry de Baere, Vincent Lebon, Lambros Tselikas, Charles Truillet
10 November 2023
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunityPraveen Bhoopathi, Amit Kumar, Anjan K Pradhan, Santanu Maji, Padmanabhan Mannangatti, Jolene J Windle, Mark A Subler, Dongyu Zhang, Vignesh Vudatha, Jose G Trevino, Esha Madan, Azeddine Atfi, Devanand Sarkar, Rajan Gogna, Swadesh K DasSee the full list of authors
7 November 2023
Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosisÁngela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani, Jose Gonzalez-Gomariz, Celia Gomar, Joan Salvador Russo-Cabrera, Irene Olivera, Assunta Cirella, Myriam Fernandez-Sendin, Maite Alvarez, Alvaro Teijeira, Cigdem Atay, José Medina-Echeverz, Maria Hinterberger, Hubertus HochreinSee the full list of authors
2 November 2023
Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hostsMargaret Veitch, Kimberly Beaumont, Rebecca Pouwer, Hui Yi Chew, Ian H Frazer, H Peter Soyer, Scott Campbell, Brian W Dymock, Andrew Harvey, Terrie-Anne Cock, James W Wells
7 September 2023
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironmentSantiago Ponce, Susana Cedrés, Charles Ricordel, Nicolas Isambert, Santiago Viteri, Mercedes Herrera-Juarez, Alex Martinez-Marti, Alejandro Navarro, Mathieu Lederlin, Xavier Serres, Jon Zugazagoitia, Sylvia Vetrhus, Magnus Jaderberg, Thomas Birkballe Hansen, Victor LevitskySee the full list of authors
3 September 2023
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancerRenato Brito Baleeiro, Peng Liu, Louisa S Chard Dunmall, Carmela Di Gioia, Ai Nagano, Lauren Cutmore, Jun Wang, Claude Chelala, Lydon Wainaina Nyambura, Peter Walden, Nicholas Lemoine, Yaohe Wang
16 August 2023